<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">8907828</journal-id>
<journal-id journal-id-type="pubmed-jr-id">20554</journal-id>
<journal-id journal-id-type="nlm-ta">J Psychopharmacol</journal-id>
<journal-id journal-id-type="iso-abbrev">J. Psychopharmacol. (Oxford)</journal-id>
<journal-title-group>
<journal-title>Journal of psychopharmacology (Oxford, England)</journal-title>
</journal-title-group>
<issn pub-type="ppub">0269-8811</issn>
<issn pub-type="epub">1461-7285</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">31264943</article-id>
<article-id pub-id-type="pmc">6894490</article-id>
<article-id pub-id-type="doi">10.1177/0269881119858304</article-id>
<article-id pub-id-type="manuscript">NIHMS1060650</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Brain circuitry, behavior and cognition: a randomized, placebo-controlled trial of donepezil in fragile X syndrome</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Bruno</surname>
<given-names>Jennifer L.</given-names>
</name>
<degrees>Ph.D.</degrees>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="author-notes" rid="FN1">*</xref>
<xref ref-type="corresp" rid="CR1">†</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hosseini</surname>
<given-names>S.M. Hadi</given-names>
</name>
<degrees>Ph.D.</degrees>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="author-notes" rid="FN1">*</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lightbody</surname>
<given-names>Amy A.</given-names>
</name>
<degrees>Ph.D.</degrees>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Manchanda</surname>
<given-names>Mai K.</given-names>
</name>
<degrees>Psy.D.</degrees>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Reiss</surname>
<given-names>Allan L.</given-names>
</name>
<degrees>M.D.</degrees>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
</contrib-group>
<aff id="A1"><label>1</label>Center for Interdisciplinary Brain Sciences Research, Stanford University.</aff>
<aff id="A2"><label>2</label>Department of Radiology, Stanford University.</aff>
<aff id="A3"><label>3</label>Department of Pediatrics, Stanford University.</aff>
<author-notes>
<fn fn-type="equal" id="FN1">
<label>*</label>
<p id="P1">Authors contributed equally to the work</p>
</fn>
<corresp id="CR1"><label>†</label>To whom correspondence should be addressed: 401 Quarry Road, Palo Alto, CA 94304, Phone: 818-415-9119, Fax: (650) 724-4761, <email>jenbruno@stanford.edu</email></corresp>
<fn fn-type="COI-statement" id="FN4">
<p id="P42">Declaration of Interest: Dr. Bruno reports consulting for Balance Pharmaceuticals regarding clinical trial data for research in Down syndrome. The remaining authors report no conflicts of interest.</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>25</day>
<month>11</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="epub">
<day>02</day>
<month>7</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="ppub">
<month>8</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>01</day>
<month>8</month>
<year>2020</year>
</pub-date>
<volume>33</volume>
<issue>8</issue>
<fpage>975</fpage>
<lpage>985</lpage>
<!--elocation-id from pubmed: 10.1177/0269881119858304-->
<abstract id="ABS1">
<sec id="S1">
<title>Background:</title>
<p id="P2">Fragile X syndrome (FXS), the most common inherited cause for intellectual disability, is associated with alterations in cholinergic among other neurotransmitter systems. The present study investigated the effects of donepezil hydrochloride, a cholinesterase inhibitor that has potential to correct aberrant cholinergic signaling.</p>
</sec>
<sec id="S2">
<title>Method:</title>
<p id="P3">Forty-two individuals with FXS (mean age=19.61) were randomized to receive 2.5mg-10.0 mg of donepezil (N=20, 7 females) or placebo (N=22, 8 females) per day. One individual in the active group withdrew at week 7. Outcomes included the contingency naming test, the aberrant behavior checklist, and behavior and brain activation patterns during a functional MRI (fMRI) gaze discrimination task.</p>
</sec>
<sec id="S3">
<title>Results:</title>
<p id="P4">There were no significant differences between active and placebo groups on cognitive (contingency naming task) or behavioral (total score or subscales of the aberrant behavior checklist) outcomes. At baseline, the active and placebo groups did not differ in fMRI activation patterns during the gaze task. After 12 weeks of treatment the active group displayed reduced activation in response to the averted vs. direct gaze contrast, relative to the placebo group, in the left superior frontal gyrus.</p>
</sec>
<sec id="S4">
<title>Conclusions:</title>
<p id="P5">Reduced functional brain activation for the active group may represent less arousal in response to direct eye gaze, relative to the placebo group. Change in fMRI activation patterns may serve as a more sensitive metric and predictor of response to treatment when compared to cognitive and behavioral assessments. Our results suggest that donepezil may have an impact on brain functioning, but longer term follow up and concomitant behavioral intervention may be required to demonstrate improvement in cognition and behavior.</p>
</sec>
</abstract>
</article-meta>
</front>
</article>
</pmc-articleset>